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Efforts to improve cancer outcomes have led to the introduction of
policies to enable ‘fast-track’ referrals from primary to secondary care
for patients with possible cancer. Although these schemes, also known
as ‘two-week-wait’ referrals, have been successful in shortening diag-
nostic intervals [1,2], their usefulness is limited to patients who present
with ‘alarm’ symptoms of relatively high predictive value for neoplastic
disease [1,3]. In contrast, achieving a prompt diagnostic resolution in
the approximate half of all cancer patients who initially present with
non-specific and lower risk symptoms remains a challenge [1,2]. To
address this problem, hospital-based multi-disciplinary diagnostic ser-
vices have been recently introduced in Denmark and England for pa-
tients with non-specific symptoms [4,5]. Two Danish studies published
recently in this Journal add substantially to relevant emerging evidence
[6,7].
An important characteristic of a diagnostic service is its diagnostic
yield (also known as ‘risk level’ or ‘conversion rate’) for detection of
cancer. In principle, unselected patients with non-specific symptoms
would be expected to have diagnostic yields for cancer that are lower to
that observed for patients with symptoms of relatively high predictive
value (in England, currently 8% of patients investigated for ‘alarm’
symptoms are found to have cancer, https://fingertips.phe.org.uk). In
contrast, both recent studies in this Journal and earlier evaluations of
Danish diagnostic centres for patients with non-specific (non-alarm)
symptoms report diagnostic yield estimates for cancer ranging from
11% to 21%, clearly exceeding the values observed in English patients
with alarm symptoms [6–11] (Table 1). Understanding the likely un-
derlying mechanisms by which these relatively high diagnostic yields
are achieved is critical to enable the most useful translation of the
pioneering Danish experience to other healthcare system settings.
Danish studies describe the presence of substantial pre-referral in-
vestigative activity (triaging) which involves the use of several primary
care tests before a decision to refer patients with non-specific symptoms
to multi-disciplinary diagnostic centres. Relevant triage investigations
include blood and urine tests and diagnostic imaging, including CT
scans (see Table 1 – column entitled ‘Triage in primary care’) [6–9,11].
This triaging process results in the selection of a patient group at ap-
preciable risk of cancer - or other serious illness.
Beyond the critical role of primary care triage, some patients re-
ferred to multi-disciplinary diagnostic centres are reported as having
symptoms of relatively high predictive value. This is in spite of the
intended primary use of these services for investigation of patients with
non-specific symptoms. As reported recently in this Journal, Næser
et al. indicate that although the great majority of all referred patients
(85%) had non-specific symptoms of low predictive value (such as
weight loss, fatigue, or malaise), nearly 6 out of 10 referred patients
had one or more ‘focal’ symptoms including certain ‘alarm’ symptoms,
such as change in bowel habit (present in 18%), lump (6%), blood in
stool (4%) and dysphagia (4%) [7].
Therefore, the diagnostic yields reported for Danish multi-dis-
ciplinary diagnostic centres are unlikely to simply reflect the diagnostic
reasoning skills or the clinical intuition of the referring primary care
physicians [12,13]. Rather, patients referred into the Danish non-spe-
cific symptoms pathway seem to represent a population at relatively
high risk of cancer, selected through smart, primary care triaging.
Further elucidation of ‘risk enrichment’ mechanisms can enable the
most useful translation of the pioneering Danish experience to other
country contexts. It is particularly important to establish how the
likelihood ratios of combinations of signs, symptoms and abnormal test
results, could inform referral and investigation algorithms, to optimise
cost-effectiveness and volume of referrals [14]. It is hoped that the
ongoing evaluations of the recently developed English multi-dis-
ciplinary diagnostic centres will help to generate valuable relevant
https://doi.org/10.1016/j.canep.2018.03.011
Received 21 March 2018
⁎ Corresponding author.
E-mail address: alice.forster@ucl.ac.uk (A.S. Forster).
Cancer Epidemiology 54 (2018) 101–103
1877-7821/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
T
Ta
bl
e
1
C
ha
ra
ct
er
is
ti
cs
of
st
ud
ie
s
ev
al
ua
ti
ng
no
n-
sp
ec
ifi
c
sy
m
pt
om
pa
th
w
ay
s.
Le
ad
au
th
or
,
ye
ar
C
ri
te
ri
a
fo
r
en
tr
y
to
pa
th
w
ay
Tr
ia
ge
in
pr
im
ar
y
ca
re
Tr
ia
ge
in
se
co
nd
ar
y
ca
re
Se
tt
in
g
N
Ti
m
e
pe
ri
od
D
ia
gn
os
ti
c
yi
el
d
fo
r
ca
nc
er
D
ia
gn
os
ti
c
yi
el
d
fo
r
ot
he
r
di
ag
no
se
s
Bi
sl
ev
et
al
.[
8]
“P
at
ie
nt
s
w
it
h
se
ri
ou
s
no
n-
sp
ec
ifi
c
sy
m
pt
om
s
an
d
si
gn
s
of
ca
nc
er
”
G
P
pe
rf
or
m
s
bl
oo
d
&
ur
in
e
te
st
s,
C
T
of
th
or
ax
,a
bd
om
en
&
pe
lv
is
“p
ri
or
to
fu
rt
he
r
ev
al
ua
ti
on
an
d
di
ag
no
st
ic
s
at
th
e
ho
sp
it
al
”
Fi
rs
t,
do
ct
or
,
nu
rs
e
an
d
pa
ti
en
t
go
th
ro
ug
h
m
ed
ic
al
hi
st
or
y/
sy
m
pt
om
s.
Th
en
ph
ys
ic
al
ex
am
in
at
io
n
an
d
pr
ev
io
us
ly
pe
rf
or
m
ed
te
st
s
re
vi
ew
ed
.T
he
n
in
di
vi
du
al
pl
an
fo
r
pa
ti
en
t
pr
ep
ar
ed
A
ar
hu
s
ho
sp
it
al
,
D
en
m
ar
k
32
3
20
11
–2
01
3
18
%
33
%
In
ge
m
an
et
al
.
[9
]
“P
at
ie
nt
s
w
it
h
se
ri
ou
s
no
n-
sp
ec
ifi
c
sy
m
pt
om
s”
“i
f
ca
nc
er
is
su
sp
ec
te
d
al
th
ou
gh
no
al
ar
m
sy
m
pt
om
s”
D
ep
en
di
ng
on
ho
sp
it
al
lo
ca
ti
on
:
G
P
pe
rf
or
m
s
bl
oo
d
&
ur
in
e
te
st
s,
pl
us
ab
do
m
in
al
ul
tr
as
ou
nd
&
ch
es
t
X
-r
ay
;o
r
C
T
of
ch
es
t,
ab
do
m
en
&
pe
lv
is
.R
ef
er
ra
l
to
di
ag
no
st
ic
un
it
ba
se
d
on
fi
nd
in
gs
of
th
es
e
te
st
s
D
ia
gn
os
ti
c
un
it
co
nd
uc
ts
fu
rt
he
r
in
ve
st
ig
at
io
ns
(e
.g
.b
lo
od
te
st
s,
di
ag
no
st
ic
im
ag
in
g,
en
do
sc
op
ie
s
an
d
bi
op
si
es
)
on
ba
si
s
of
sy
m
pt
om
s/
cl
in
ic
al
fi
nd
in
gs
.E
as
y
ac
ce
ss
to
ra
ng
e
of
m
ed
ic
al
sp
ec
ia
lis
ts
A
ar
hu
s
&
Si
lk
eb
or
g
ho
sp
it
al
s,
D
en
m
ar
k
1,
73
2
20
12
–2
01
3
16
%
N
ot
re
po
rt
ed
M
os
eh
ol
m
et
al
.
[1
0]
“P
at
ie
nt
s
w
it
h
se
ri
ou
s
no
n-
sp
ec
ifi
c
sy
m
pt
om
s
an
d
si
gn
s
of
ca
nc
er
”
N
ot
de
sc
ri
be
d
N
ot
de
sc
ri
be
d
Fo
ur
ho
sp
it
al
s
in
th
e
C
ap
it
al
R
eg
io
n
of
D
en
m
ar
k
1,
12
7
20
13
–2
01
4
20
%
N
ot
re
po
rt
ed
Jø
rg
en
se
n
et
al
.
[1
1]
“P
at
ie
nt
s
w
it
h
no
n-
or
ga
n-
sp
ec
ifi
c
sy
m
pt
om
s
an
d
si
gn
s
of
ca
nc
er
,w
ho
w
er
e
he
al
th
y
en
ou
gh
fo
r
an
ou
tp
at
ie
nt
co
ur
se
”
G
P
or
ot
he
r
ho
sp
it
al
de
pa
rt
m
en
t
re
fe
rs
pa
ti
en
ts
Bl
oo
d
te
st
&
ch
es
t
x-
ra
y
pe
rf
or
m
ed
pr
io
r
to
vi
si
t
fo
r
di
ag
no
st
ic
un
it
.“
O
n
ba
si
s
of
in
fo
rm
at
io
n
av
ai
la
bl
e
at
re
fe
rr
al
th
e
ph
ys
ic
ia
n”
de
te
rm
in
es
te
st
s
re
qu
ir
ed
be
fo
re
ap
po
in
tm
en
t.
Fu
rt
he
r
in
ve
st
ig
at
io
ns
pl
an
ne
d
at
fi
rs
t
vi
si
t
N
or
th
Ze
al
an
d
ho
sp
it
al
,
D
en
m
ar
k
82
5
20
13
–2
01
4
17
%
N
ot
re
po
rt
ed
M
os
eh
ol
m
an
d
Li
nd
ha
rd
t
[6
]
“P
at
ie
nt
s
su
sp
ec
te
d
of
ha
vi
ng
ca
nc
er
du
e
to
se
ri
ou
s
no
n-
sp
ec
ifi
c
sy
m
pt
om
s”
G
P
pe
rf
or
m
s
di
ag
no
st
ic
im
ag
in
g
&
bl
oo
d
&
ur
in
e
te
st
s
&
re
fe
rr
ed
to
di
ag
no
st
ic
un
it
if
re
le
va
nt
(p
ro
to
co
l
va
ri
es
ac
ro
ss
D
en
m
ar
k)
Fa
ci
lit
y
fo
r
m
ed
ic
al
in
ve
st
ig
at
io
n
an
d
ea
sy
ac
ce
ss
to
sp
ec
ia
lis
ts
A
ll
re
fe
rr
al
s
to
N
SS
C
-C
PP
,
D
en
m
ar
k
23
,9
34
20
12
–2
01
5
11
%
34
%
N
æ
se
r
et
al
.[
7]
Pa
ti
en
ts
w
it
h
no
n-
sp
ec
ifi
c
sy
m
pt
om
s
G
P
pe
rf
or
m
s
bl
oo
d
te
st
&
co
m
bi
ne
d
th
or
ac
ic
x-
ra
y
&
ul
tr
as
ou
nd
of
ab
do
m
en
.C
T
of
ch
es
t,
ab
do
m
en
&
pe
lv
is
if
ra
di
ol
og
is
t
de
em
s
re
le
va
nt
.“
G
P
in
it
ia
te
s
th
e
di
ag
no
st
ic
w
or
ku
p
on
ba
si
s
of
th
e”
re
su
lt
s.
“I
ft
he
tr
ia
ge
fu
nc
ti
on
yi
el
ds
no
ob
vi
ou
s
ex
pl
an
at
io
n
fo
r
th
e
pa
ti
en
t’s
sy
m
pt
om
s”
,G
P
re
fe
rs
to
di
ag
no
st
ic
ce
nt
re
C
en
tr
e
ru
n
by
in
te
rn
al
m
ed
ic
in
e
sp
ec
ia
lis
ts
.
In
di
vi
du
al
di
ag
no
st
ic
pr
og
ra
m
m
es
ba
se
d
on
m
ed
ic
al
hi
st
or
y
an
d
re
su
lt
s
of
pr
ev
io
us
in
ve
st
ig
at
io
ns
.A
ll
m
ed
ic
al
sp
ec
ia
lt
ie
s
re
pr
es
en
te
d
at
th
e
ce
nt
re
.C
en
tr
e
ha
s
pr
ef
er
en
ti
al
ar
ra
ng
em
en
ts
w
it
h
sp
ec
ia
lis
ts
to
sp
ee
d
up
in
ve
st
ig
at
io
ns
.C
on
cu
rr
en
tw
or
k
up
in
di
ff
er
en
t
m
ed
ic
al
sp
ec
ia
lit
ie
s
m
ay
oc
cu
r
Si
lk
eb
or
g
ho
sp
it
al
,
D
en
m
ar
k
93
8
20
12
–2
01
4
13
%
22
%
N
ic
ho
ls
on
et
al
.
[1
2]
Pa
ti
en
ts
ag
ed
≥
40
,f
or
w
ho
m
th
er
e
is
no
al
te
rn
at
iv
e
su
it
ab
le
ur
ge
nt
re
fe
rr
al
pa
th
w
ay
an
d
pr
es
en
ti
ng
w
it
h
on
e
of
si
x
pr
e-
sp
ec
ifi
ed
no
n-
sp
ec
ifi
c
sy
m
pt
om
s/
cl
in
ic
al
fi
nd
in
gs
(i
nc
lu
di
ng
‘g
ut
fe
el
in
g’
)
G
Ps
ac
ce
ss
tr
ia
ge
te
st
s
fo
r
th
es
e
pa
ti
en
ts
(b
lo
od
te
st
s,
fa
ec
al
im
m
un
oc
he
m
ic
al
te
st
in
g
an
d
lo
w
-d
os
e
co
m
pu
te
ri
se
d
to
m
og
ra
ph
y)
.
Ba
se
d
on
th
e
fi
nd
in
gs
of
th
es
e
te
st
s,
pa
ti
en
ts
ar
e
re
fe
rr
ed
vi
a
an
ur
ge
nt
re
fe
rr
al
pa
th
w
ay
fo
r
ca
nc
er
,o
r
fo
r
fu
rt
he
r
in
ve
st
ig
at
io
ns
If
ca
us
e
of
th
e
sy
m
pt
om
s
re
m
ai
ns
un
ce
rt
ai
n,
pa
ti
en
t
re
fe
rr
ed
to
a
m
ul
ti
di
sc
ip
lin
ar
y
di
ag
no
st
ic
ce
nt
re
,w
it
h
th
e
in
ve
st
ig
at
io
ns
us
ed
he
re
de
te
rm
in
ed
on
an
in
di
vi
du
al
ba
si
s
by
th
e
re
sp
on
si
bl
e
cl
in
ic
ia
n
O
xf
or
ds
hi
re
,
U
K
O
ng
oi
ng
20
17
–c
ur
re
nt
O
ng
oi
ng
O
ng
oi
ng
A.S. Forster et al. Cancer Epidemiology 54 (2018) 101–103
102
evidence in the near future [12] (Table 1).
Another key question about diagnostic services for patients with
non-specific symptoms is their likely contribution in promptly detecting
consequential illness other than cancer. Both recently published studies
from Denmark indicate that between a fifth and a third of all patients
referred to multi-disciplinary diagnostic centres were diagnosed with
clinically significant non-neoplastic disease [6,7]. Moseholm and
Lindhardt report that among referred patients, 9% were found to have
cardiovascular disease, 7% gastrointestinal disease, and 5% muscu-
loskeletal and connective tissue disorders [6]. Although further estab-
lishing the diagnostic yield for non-neoplastic diagnoses, and their
spectrum, remains important, patients are likely to value a prompt di-
agnostic resolution independently of whether a formal diagnosis is
reached or excluded as a source of their symptoms.
The speed by which diagnostic resolution can be achieved in pa-
tients with non-specific symptoms is of great interest to both patients
and planners of healthcare services. Moseholm and Lindhardt [6] report
that diagnostic resolution in the evaluated Danish diagnostic centres
was achieved after an average of four outpatient appointments during a
seven-day period, noting that in a substantial minority of patients the
diagnostic process was longer. These findings provide for a ‘reality
check’ about the concept of ‘one-stop / same-day’ evaluations, which
seem unlikely for most referred patients. However, reported diagnostic
intervals are substantially shorter than those likely to have been ex-
perienced in the absence of a scheme for the referral of patients with
non-specific symptoms.
Multidisciplinary diagnostic services represent complex healthcare
interventions [15]. Eligible patients have heterogeneous symptoms and
disease states, and the use of various investigations at multiple time
points from presentation to diagnosis creates a very high number of
combinations of test sequences. Evaluating these complex healthcare
interventions using controlled study designs would be ideal. Studies
should provide evidence about selection criteria regarding presenting
symptoms and triaging tests, and the diagnostic strategies (both within
primary care and once the patient has been received at the diagnostic
centre) associated with optimal diagnostic yield, patient safety and
cost-effectiveness. It is important to collect follow-up data on treatment
and prognosis (survival), and explore the clinical and psychological
impact of tests on patients who are referred and investigated but found
to have no important illness. The risks of over-diagnosing asymptomatic
disease unrelated to the ‘trigger’ symptomatic presentations which
would not have presented clinically during the patient’s lifetime should
also be quantified. Cost-effectiveness studies are needed to balance
potential cost savings from fewer appointments and potential earlier
diagnosis against the fact that many individuals will receive expensive
diagnostic healthcare without obvious clinical benefit and at risk of
potential harm.
In conclusion, the studies by Moseholm and Lindhardt [6] and
Næser et al. [7] recently reported in this Journal demonstrate relatively
high yields regarding the diagnosis of cancer and other important ill-
ness following referral to hospital-based diagnostic services for non-
specific symptoms. Taken together with other evidence from Denmark,
these studies highlight useful mechanisms by which the effectiveness of
such services can be optimised, critically involving an active role of
triage in primary care. Future research, ideally using controlled designs,
should aim to more fully characterise the presenting symptoms of re-
ferred patients and refine the most effective diagnostic test cascades,
together with optimal triaging protocols in both primary and secondary
care. Controlled studies evaluating these multi-faceted complex inter-
ventions, including process evaluations exploring the mechanisms by
which they work, can help to elucidate their potential effectiveness in
different clinical scenarios, and help to improve the diagnostic
experience and outcomes for the half of cancer patients who initially
present to primary care without alarm symptoms.
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